{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:55:56Z","timestamp":1790178956341,"version":"4.1.0"},"reference-count":20,"publisher":"Frontiers Media SA","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Cell. Infect. Microbiol."],"DOI":"10.3389\/fcimb.2014.00079","type":"journal-article","created":{"date-parts":[[2014,6,18]],"date-time":"2014-06-18T15:34:49Z","timestamp":1403105689000},"source":"Crossref","is-referenced-by-count":30,"title":["The potential of liposome\u00e2\u20ac\u201cencapsulated ciprofloxacin as a tularemia therapy"],"prefix":"10.3389","volume":"4","author":[{"given":"Karleigh A.","family":"Hamblin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan P.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen S.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2014,6,18]]},"reference":[{"key":"B20","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1001\/jama.286.23.2935","article-title":"Update: adverse events associated with anthrax prophylaxis among postal employees - New Jersey, New York City, and the District of Columbia Metropolitan Area, 2001","volume":"286","author":"Brechner","year":"2001","journal-title":"JAMA"},{"key":"B1","first-page":"73","article-title":"Inhaled liposomal ciprofloxacin: once a day management of respiratory infections","volume-title":"Proceedings of Respiratory Drug Delivery","author":"Bruinenberg","year":"2010"},{"key":"B2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7883\/yoken.JJID.2006.229","article-title":"Tularemia, a reemerging disease in northwest Turkey: epidemiological investigation and evaluation of treatment responses","volume":"59","author":"Celebi","year":"2006","journal-title":"Jpn. J. Infect. Dis"},{"key":"B3","first-page":"409","article-title":"Inhaled liposomal ciprofloxacin: in vitro properties and aerosol performance","volume-title":"Proceedings of Respiratory Drug Delivery","author":"Cipolla","year":"2010"},{"key":"B4","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1128\/AAC.41.6.1288","article-title":"Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice","volume":"41","author":"Conley","year":"1997","journal-title":"Antimicrob. Agents Chemother"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1001\/jama.285.21.2763","article-title":"Tularemia as a biological weapon: medical and public health management","volume":"285","author":"Dennis","year":"2001","journal-title":"J. Am. Med. Assoc"},{"key":"B6","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/infdis\/168.3.793","article-title":"Liposome-encapsulated ciprofloxacin is effective in the protection and treatment of Balb\/c mice against Francisella tularensis","volume":"168","author":"Di Ninno","year":"1993","journal-title":"J. Infect. Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1128\/AAC.02555-13","article-title":"Liposome-encapsulation of ciprofloxacin improves protection against highly virulent Francisella tularensis Schu S4 strain","volume":"58","author":"Hamblin","year":"2014","journal-title":"Antimicrob. Agents Chemother"},{"key":"B8","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1586\/14787210.6.2.231","article-title":"Tularemia: current diagnosis and treatment options","volume":"6","author":"Hepburn","year":"2008","journal-title":"Expert Rev. Anti Infect. Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1128\/AAC.30.2.260","article-title":"Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients","volume":"30","author":"LeBel","year":"1986","journal-title":"Antimicrob. Agents Chemother"},{"key":"B21","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1128\/AAC.36.5.993","article-title":"Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses","volume":"36","author":"Lettieri","year":"1992","journal-title":"Antimicrob. Agents Chemother"},{"key":"B10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1600-0463.2008.00901.x","article-title":"Evaluation of clinical, laboratory, and therapeutic features of 145 tularemia cases: the role of quinolones in oropharyngeal tularemia","volume":"116","author":"Meric","year":"2008","journal-title":"Apmis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1086\/322601","article-title":"Tularemia epidemic in northwestern Spain: clinical description and therapeutic response","volume":"33","author":"Perez-Castrillon","year":"2001","journal-title":"Clin. Infect. Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1093\/jac\/dki359","article-title":"In vivo efficacy of fluoroquinolones against systemic tularaemia infection in mice","volume":"56","author":"Piercy","year":"2005","journal-title":"J. Antimicrob. Chemother"},{"key":"B14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0924-8579(99)00121-1","article-title":"Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications","volume":"13","author":"Pinto-Alphandary","year":"2000","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B15","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1358\/dot.2012.48.5.1789474","article-title":"Inhaled antibiotics for lower respiratory tract infections: focus on ciprofloxacin","volume":"48","author":"Serisier","year":"2012","journal-title":"Drugs Today"},{"key":"B16","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1136\/thoraxjnl-2013-203207","article-title":"Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial","volume":"68","author":"Serisier","year":"2013","journal-title":"Thorax"},{"key":"B17","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ijantimicag.2006.02.006","article-title":"Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin","volume":"27","author":"Steward","year":"2006","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B18","first-page":"105","article-title":"Liposome-encapsulated ciprofloxacin for the prevention and treatment of infectious diseases by intracellular pathogens","volume-title":"Liposomes in Biomedical Applications","author":"Wong","year":"1995"},{"key":"B19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0168-3659(03)00358-4","article-title":"Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection","volume":"92","author":"Wong","year":"2003","journal-title":"J. Control. Release"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T21:09:44Z","timestamp":1716844184000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fcimb.2014.00079\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,18]]},"references-count":20,"URL":"https:\/\/doi.org\/10.3389\/fcimb.2014.00079","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,18]]}}}